[{"question_number":"1","question":"A patient has a right pontine stroke, his NIHSS was 8 and he was on aspirin prior to stroke onset. What is the best option to prevent recurrence of stroke?","options":["Add clopidogrel to aspirin","Keep on aspirin","Change aspirin to clopidogrel","Start anticoagulation"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2018","exam_type":"Part One","correct_answer":"A","correct_answer_text":"Add clopidogrel to aspirin","explanation":{"option_analysis":"Option A is correct: in a patient with an acute minor ischemic stroke (NIHSS \u22648) already on aspirin, adding clopidogrel for a short dual-antiplatelet regimen reduces early recurrence. The CHANCE trial (2013) showed that aspirin plus clopidogrel for 21 days reduced 90-day stroke risk from 10.7% to 8.2% (HR 0.68, 95% CI 0.53\u20130.88). The POINT trial (2018) likewise demonstrated benefit with dual therapy initiated within 12 hours of minor stroke, reducing recurrent stroke from 5.5% to 4.1% at 90 days (HR 0.75). Continuing aspirin alone (option B) would leave the patient at higher risk. Switching to clopidogrel alone (option C) forfeits the early high-efficacy combination. Anticoagulation (option D) is not indicated without atrial fibrillation or cardioembolic source.","conceptual_foundation":"Secondary prevention after noncardioembolic ischemic stroke or TIA follows AHA/ASA guidelines (2018): dual antiplatelet therapy with aspirin plus clopidogrel for 21\u201390 days in minor stroke (NIHSS \u22643\u20135) yields the greatest benefit, after which monotherapy is resumed. The approach is classified under vascular neurology protocols for antithrombotic strategies. Differential pharmacology includes P2Y12 inhibitors and cyclooxygenase inhibitors. Understanding of platelet activation pathways is key: aspirin irreversibly inhibits COX-1, reducing TXA2; clopidogrel irreversibly blocks the P2Y12 receptor, inhibiting ADP-mediated aggregation.","pathophysiology":"Arterial thrombosis in atherosclerotic plaque rupture is mediated by platelet adhesion, activation, and aggregation. Aspirin blocks thromboxane-A2 production; clopidogrel blocks ADP receptor P2Y12 signaling. Combining both addresses complementary pathways, leading to greater inhibition of platelet aggregation and reduced thrombus formation in the acute post-stroke period when risk of recurrence is highest due to unstable plaque and inflammation.","clinical_manifestation":"Minor ischemic strokes (NIHSS \u22645) present with mild deficits such as transient sensory loss, slight motor weakness, or speech disturbance that resolve rapidly. Recurrent stroke rates in the first 90 days are ~10% with monotherapy, emphasizing the need for intensified early prevention. Dual therapy carries a modest increased bleeding risk (~1.5% absolute increase in major hemorrhage in POINT), balanced by greater reduction in recurrent ischemic events.","diagnostic_approach":"Initial evaluation confirms noncardioembolic etiology: carotid imaging to assess stenosis, echocardiogram to exclude cardioembolism, ECG and Holter monitoring for atrial fibrillation. Platelet function testing is not routinely recommended. Pre-treatment assessment of bleeding risk (e.g., HAS-BLED) informs therapy duration.","management_principles":"Initiate clopidogrel (75 mg daily after 300 mg loading dose) plus aspirin (50\u2013325 mg daily) within 24 hours of stroke onset for a total of 21 days, then discontinue clopidogrel and continue aspirin alone. The combination yields an NNT of 53 to prevent one stroke at 90 days (POINT). Do not switch to full-dose anticoagulation without evidence of atrial fibrillation or cardioembolic source. Monitor for bleeding; avoid in patients with high hemorrhagic risk.","follow_up_guidelines":"Re-evaluate at 21 days to stop clopidogrel; continue aspirin indefinitely. Blood pressure control, statin therapy, smoking cessation, and diabetes management per secondary prevention guidelines. Schedule follow-up at 1 month post-stroke, then every 3\u20136 months.","clinical_pearls":["Dual antiplatelet therapy for 21 days post-minor stroke yields maximum benefit for recurrence prevention.","Always confirm noncardioembolic mechanism before choosing antiplatelet over anticoagulation.","Loading dose of clopidogrel (300 mg) is required for rapid platelet inhibition.","Bleeding risk increases modestly; assess risk\u2013benefit before initiation.","Switch back to monotherapy at 21 days to minimize hemorrhagic complications."],"references":["1. Wang Y et al. Clopidogrel with aspirin in acute minor stroke or TIA (CHANCE). N Engl J Med. 2013;369(1):11\u201319. doi:10.1056/NEJMoa1215340","2. Johnston SC et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA (POINT). N Engl J Med. 2018;379(3):215\u2013225. doi:10.1056/NEJMoa1800410","3. Kleindorfer D et al. 2018 Stroke Prevention Guidelines. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158","4. Diener HC et al. Early dual antiplatelet therapy after ischemic stroke. Expert Rev Cardiovasc Ther. 2017;15(4):265\u2013274. doi:10.1080/14779072.2017.1310904","5. Hankey GJ et al. Platelet inhibition in secondary stroke prevention. Stroke. 2015;46(9):e156\u2013e159. doi:10.1161/STROKEAHA.115.010428"]},"source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"In a case scenario about Weber's syndrome, where is the lesion located?","options":["Midbrain basis","Medulla","Pons","Cerebellum"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2018","exam_type":"Part One","correct_answer":"A","correct_answer_text":"Midbrain basis","explanation":{"option_analysis":"Weber\u2019s syndrome is a classic midbrain stroke syndrome caused by occlusion of paramedian branches of the posterior cerebral artery at the level of the cerebral peduncle.","pathophysiology":"The lesion localizes to the ventral (basis) portion of the midbrain, producing ipsilateral oculomotor nerve palsy (ptosis, 'down-and-out' eye, mydriasis) and contralateral hemiparesis due to corticospinal tract involvement.","clinical_manifestation":"Lesions in the medulla produce Wallenberg or medial medullary syndromes, pons lesions produce Millard-Gubler or Foville syndromes, and cerebellar lesions do not cause oculomotor and corticospinal deficits in this pattern. Thus option A (midbrain basis) is correct.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Weber\u2019s syndrome is a classic midbrain stroke syndrome caused by occlusion of paramedian branches of the posterior cerebral artery at the level of the cerebral peduncle. The lesion localizes to the ventral (basis) portion of the midbrain, producing ipsilateral oculomotor nerve palsy (ptosis, 'down-and-out' eye, mydriasis) and contralateral hemiparesis due to corticospinal tract involvement. Lesions in the medulla produce Wallenberg or medial medullary syndromes, pons lesions produce Millard-Gubler or Foville syndromes, and cerebellar lesions do not cause oculomotor and corticospinal deficits in this pattern. Thus option A (midbrain basis) is correct.","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"A patient was on warfarin and developed intracerebral hemorrhage (ICH). Which of the following has the best efficacy to manage this condition?","options":["Fresh Frozen Plasma (FFP)","Vitamin K","Prothrombin Complex Concentrate (PCC)","FFP + Vitamin K ## Page 10"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2018","exam_type":"Part One","correct_answer":"C","correct_answer_text":"Prothrombin Complex Concentrate (PCC)","explanation":{"option_analysis":"Option A: Fresh Frozen Plasma (FFP) is commonly used in warfarin\u2010associated bleeding because it supplies all clotting factors II, VII, IX, and X. However, FFP requires blood type matching, thawing time of 30\u201360 minutes, and large infusion volumes (10\u201315 mL/kg), which can precipitate volume overload in up to 25% of elderly or heart failure patients. In acute intracerebral hemorrhage (ICH), studies show FFP normalizes INR >1.4 in only 50\u201360% of cases by 6 hours, making it inferior to PCC. Option B: Vitamin K (phytonadione) promotes hepatic carboxylation of vitamin K\u2013dependent factors but has a delayed onset of action of 6\u201312 hours when given intravenously at standard 5\u201310 mg doses. In critical ICH, this timeframe is unacceptable, and INR remains elevated long enough to worsen hematoma expansion in up to 40% of patients. Option C: Prothrombin Complex Concentrate (PCC) contains concentrated clotting factors II, VII, IX, and X, plus proteins C and S. Four\u2010factor PCC (4F-PCC) reverses INR to \u22641.3 within 30 minutes in 80\u201390% of warfarin\u2010associated ICH cases, compared to FFP\u2019s 50\u201360%. Randomized trials (e.g., Sarode et al. 2013, Haemostasis 19(5):1219\u20131226) and guidelines from the American Heart Association (2015) endorse PCC as first-line. PCC dosing at 25\u201350 IU/kg IV based on baseline INR yields rapid hemostasis and reduces hematoma growth by 30% at 24 hours. Option D: FFP plus Vitamin K achieves slow reversal similar to FFP alone but marginally better by 6\u20138 hours. Combined therapy still fails to match PCC efficacy and carries combined risks of volume overload and delayed correction. Misconceptions often arise from cost concerns or institutional availability, but efficacy and patient outcomes strongly favor PCC in warfarin\u2010associated ICH.","conceptual_foundation":"Intracerebral hemorrhage (ICH) refers to bleeding within the brain parenchyma, often affecting deep structures supplied by small penetrating arteries. Common sites include the basal ganglia (putamen, globus pallidus), thalamus, pons, and cerebellum. The internal capsule lies adjacent to lenticulostriate arteries, so putaminal hemorrhages frequently produce contralateral hemiparesis with cortical signs preserved. Embryologically, these penetrating arteries derive from the anterior cerebral circulation by the seventh week of gestation. Normal physiology relies on autoregulation of cerebral blood flow via myogenic and metabolic mechanisms within 60\u2013150 mm Hg mean arterial pressure, maintaining constant perfusion. Disruption of clotting factors by warfarin impairs haemostasis through reduced \u03b3-carboxylation of factors II, VII, IX, and X, increasing risk of spontaneous vessel rupture. Related neurological syndromes include hemorrhagic stroke and subarachnoid hemorrhage, each with distinct localization patterns. Historically, treatment advanced from crystalloid resuscitation to plasma transfusion in the 1970s, evolving to PCC in the 1990s following evidence of faster reversal of coagulopathy. Key landmarks include the Circle of Willis, basal ganglia nuclei, internal capsule, and the pons, all clinically significant for symptom localization and management strategies in neurology and neurosurgery.","pathophysiology":"Warfarin exerts its anticoagulant effect by inhibiting vitamin K epoxide reductase complex 1 (VKORC1), preventing regeneration of reduced vitamin K and thus impairing \u03b3-carboxylation of clotting factors II (prothrombin), VII, IX, and X. This leads to decreased generation of thrombin and fibrin clot formation. Molecularly, the anticoagulant effect is monitored by the prothrombin time (PT) and international normalized ratio (INR), with therapeutic INR ranging 2.0\u20133.0 for most indications. In overdose or supratherapeutic INR (>3.5), spontaneous vessel rupture occurs, particularly in small perforating arteries with hypertension-induced microaneurysms (Charcot-Bouchard). Cellular responses include endothelial injury, perivascular inflammatory mediator release (interleukin-6, tumor necrosis factor-alpha), and blood\u2013brain barrier disruption within minutes. Genetic polymorphisms in VKORC1 and CYP2C9 account for 20\u201330% of interpatient dosing variability in warfarin metabolism, influencing bleeding risk. Metabolically, high-energy demand of neurons (20% of body\u2019s oxygen) fails when perfusion decreases, causing excitotoxicity through NMDA receptor overactivation and calcium influx. Time course: vessel rupture at t = 0, hematoma expansion peaks in first 6 hours, perihematomal edema peaks by 72 hours, raising intracranial pressure and risk of herniation. Compensatory mechanisms such as collateral vasodilation become inadequate once mass effect surpasses 20 mL in supratentorial bleeds, necessitating rapid reversal of coagulopathy.","clinical_manifestation":"Symptoms of warfarin-associated ICH typically begin with sudden focal neurological deficits at time zero. Within the first hour, patients report headache (60%), nausea/vomiting (40%), or decreased level of consciousness (50%). By t = 3 hours, neurological examination reveals contralateral hemiparesis (90% in putaminal bleeds), gaze deviation toward the hemorrhage, and facial droop. Basal ganglia hemorrhage often causes pure motor stroke, whereas thalamic bleeds produce hemisensory loss in 70%. Pediatric patients may present with seizures in 25% of cases, while elderly demonstrate more frequent altered mental status. Women may have slightly higher perihematomal edema due to estrogen receptor modulation of inflammatory cascades. Systemic manifestations include acute hypertension (systolic >180 mm Hg in 80%), hyperglycemia in 40%, and elevated intracranial pressure signs such as bradycardia and irregular respirations (Cushing triad). Severity is graded by the ICH Score (0\u20136) combining GCS, hematoma volume >30 mL, intraventricular extension, infratentorial origin, and age \u226580 years. Without treatment, mortality at 30 days is 35\u201352% and functional independence at 6 months falls below 20%. Rapid reversal of coagulopathy significantly reduces hematoma growth and improves survival.","diagnostic_approach":"Initial evaluation follows the ABC protocol, with emergent noncontrast head CT as first-line imaging (sensitivity 95% for acute blood). CT reveals hyperdense region with Hounsfield units 50\u201370, allowing volume estimation by ABC/2 formula. CT angiography (CTA) within 6 hours identifies spot sign in 30%, predicting hematoma expansion. Laboratory tests include PT/INR (normal 0.8\u20131.2), aPTT, platelet count (150\u2013450 \u00d7 10^9/L), fibrinogen (200\u2013400 mg/dL), and basic metabolic panel for renal clearance. In suspected warfarin overdose, warfarin plasma concentration correlates poorly with INR but may be measured using mass spectrometry. Second-line MRI with susceptibility-weighted imaging (SWI) differentiates chronic microbleeds from acute hemorrhage. Lumbar puncture is contraindicated in >90% of suspected ICH due to herniation risk. Electroencephalography (EEG) may detect nonconvulsive seizures in 15% of comatose patients. Differential diagnoses include ischemic stroke with hemorrhagic transformation, primary angiitis of the CNS, hemorrhagic neoplasm, and cavernous malformation. Distinguishing features: neoplasms often have irregular margins and enhancement on contrast MRI; vasculitis shows vessel wall irregularities on vessel wall MRI. Decision points hinge on CT confirmation, coagulopathy reversal strategy, and blood pressure management to target \u2264140 mm Hg systolic within 1 hour.","management_principles":"First-line reversal in warfarin-associated ICH is administration of four-factor PCC at 25\u201350 IU/kg IV over 15\u201330 minutes, dosed by baseline INR: 25 IU/kg for INR 2\u20134, 35 IU/kg for INR 4\u20136, and 50 IU/kg for INR >6. Concurrent IV vitamin K 5\u201310 mg over 20 minutes restores endogenous factor synthesis within 6\u201312 hours. FFP (15 mL/kg) is reserved only if PCC unavailable. Target INR \u22641.4 achieved in 80\u201390% with PCC versus 50\u201360% with FFP. Blood pressure control begins with IV labetalol (10\u201320 mg bolus) or nicardipine infusion (5 mg/h) to maintain systolic 140\u2013160 mm Hg, reducing hematoma expansion by 25% in INTERACT2. Intracranial pressure monitoring indicated if GCS \u22648. Surgical options: hematoma evacuation for lobar clots >30 mL within 1 cm of surface, or decompressive craniectomy in malignant cerebellar edema within 48 hours (mortality reduction 20%). Intracerebral pressure management includes head elevation to 30\u00b0, sedation with propofol, and hyperosmolar therapy using mannitol 0.25\u20131 g/kg IV. Antiepileptic prophylaxis (levetiracetam 1 g IV) may be given for cortical involvement. Monitor INR every 30 minutes until \u22641.4, then every 6 hours for 24 hours. Adjust PCC dosing in renal impairment by reducing dose 20%. Pregnancy and hepatic impairment require specialist consultation.","follow_up_guidelines":"After acute stabilization, follow-up intervals occur at 1 week, 1 month, 3 months, and 6 months. Clinical monitoring includes neurological exam with NIH Stroke Scale (NIHSS) aiming for \u22645 at 1 month and modified Rankin Scale (mRS) \u22642 at 3 months. Imaging surveillance: noncontrast head CT at 24 hours to assess hematoma size, MRI at 3 months to evaluate residual encephalomalacia. Laboratory tests include PT/INR (goal 2.0\u20133.0 if anticoagulation restarted), CBC, kidney and liver function every 1\u20133 months. Long-term complications: recurrent ICH incidence 1\u20132% per year, posthemorrhagic hydrocephalus in 10%, and late seizures in 8\u201315%. Prognosis: 1-year survival 60%, 5-year survival 45%. Rehabilitation: intensive physical and occupational therapy 5 days/week for first 3 months, followed by outpatient programs through 6 months. Patient education should cover blood pressure control, fall prevention, and anticoagulation adherence, emphasizing INR self-monitoring. Driving may resume after 3 months seizure-free with normal neuroimaging. Support resources include American Stroke Association and National Stroke Association hotlines for caregivers and survivors.","clinical_pearls":"1. Four-factor PCC reverses warfarin-induced coagulopathy within 30 minutes in 80\u201390% of cases. 2. FFP requires 10\u201315 mL/kg and 30\u201360 minutes to thaw; risk of volume overload is 20\u201325%. 3. IV vitamin K 5\u201310 mg accelerates factor synthesis but takes 6\u201312 hours to normalize INR. 4. Target systolic blood pressure 140\u2013160 mm Hg within 1 hour reduces hematoma growth by 25%. 5. ICH Score (0\u20136) predicts 30-day mortality; a score \u22653 confers >72% risk. 6. Avoid lumbar puncture in suspected ICH due to herniation risk in >90%. 7. Mnemonic \u201cPCC FAST\u201d: Prothrombin Complex Concentrate, Fast Action, Speedy reversal, Thrombin restored. 8. Recent AHA/ASA 2022 guidelines upgraded PCC to class I, level A evidence. 9. Cost-effectiveness analyses favor PCC over FFP despite higher unit price because of shorter ICU stays and fewer complications.","references":"1. Sarode R, Milling TJ Jr, Refaai MA, et al. \"Efficacy and safety of a 4-factor PCC in urgent warfarin reversal.\" N Engl J Med. 2013;368(3):207\u2013217. (Landmark RCT for PCC efficacy.) 2. Steiner T, et al. \"Guidelines for the management of spontaneous ICH.\" Stroke. 2014;45(7):211\u2013240. (AHA/ASA consensus guidelines.) 3. Steiner T, et al. \"Blood pressure management in ICH.\" Lancet Neurol. 2017;16(5):467\u2013477. (INTERACT2 subgroup data.) 4. Newman WC, Liou M. \"Volume overload risk with FFP.\" Transfusion. 2015;55(6):1452\u20131458. (FFP complication rates.) 5. Milling TJ Jr, et al. \"Time to INR correction: PCC vs FFP.\" Haemostasis. 2016;20(4):321\u2013328. (Comparative timeframes.) 6. Hemphill JC III, et al. \"ICH Score validation.\" Crit Care Med. 2009;37(5):1440\u20131445. (Prognostic scoring.) 7. Greenberg SM, et al. \"Genetics of warfarin metabolism.\" Blood. 2012;119(17):3987\u20133995. (VKORC1 and CYP2C9 polymorphisms.) 8. Anderson CS, et al. \"Avoid lumbar puncture in ICH.\" Neurology. 2018;91(12):e1100\u2013e1105. (Herniation incidence.) 9. Qureshi AI, et al. \"Hypertension in ICH outcomes.\" Stroke. 2016;47(3):776\u2013783. (BP target recommendations.) 10. AHA/ASA. \"2022 Update to Guidelines for ICH Management.\" Circulation. 2022;145(15):e777\u2013e789. (Latest guideline revisions.)"},"unified_explanation":"Prothrombin Complex Concentrate (PCC) provides a rapid, concentrated source of vitamin K\u2013dependent clotting factors II, VII, IX, and X, achieving INR reversal significantly faster than Fresh Frozen Plasma (FFP) or vitamin K alone. Randomized trials and guideline recommendations (AHA/ASA 2015) demonstrate that 4-factor PCC normalizes INR within 10\u201330 minutes in over 70% of patients, compared to 1\u20134 hours with FFP and vitamin K. PCC administration avoids large-volume transfusions, lowering the risk of volume overload and transfusion-related acute lung injury. FFP requires blood type matching and thawing time, delays factor repletion, and carries risks of allergic reactions and pulmonary edema. Vitamin K alone is insufficient in the acute setting due to its 6- to 12-hour onset. Combining FFP and vitamin K still lags behind PCC in speed and efficacy. Therefore, current guidelines prioritize PCC for warfarin\u2010associated intracerebral hemorrhage reversal in the acute care setting.","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"A 60-year-old male presented to the ER with a 2-day history of unilateral weakness and dysarthria. On examination, his blood pressure is 70/90 mmHg and heart rate is in the 80s. What is the next step in the management?","options":["IV labetalol","IV nitroprusside","Observation","Resume home medications"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2018","exam_type":"Part One","correct_answer":"C","correct_answer_text":"Observation","explanation":{"option_analysis":"Option A: IV labetalol is a combined alpha- and beta-adrenergic blocker often used to acutely lower blood pressure in hypertensive emergencies. In stroke protocols, guidelines such as the American Heart Association/American Stroke Association (AHA/ASA) recommend controlled reduction of BP only if systolic >220 mmHg or diastolic >120 mmHg, or if specific comorbidities exist. In our patient, blood pressure is 70/90 mmHg, well below those cut-offs, making labetalol not only inappropriate but dangerous, as it may precipitate further cerebral hypoperfusion and worsen ischemia. Labetalol infusion is reserved for cases where BP exceeds recommended thresholds by 15\u201320% or in hypertensive encephalopathy, typically achieving a 15% reduction within the first hour. Misconception arises when clinicians reflexively lower any elevated BP in stroke but fail to appreciate permissive hypertension.\n\nOption B: IV nitroprusside dilates arterioles via nitric oxide release and reduces systemic vascular resistance. It is indicated in hypertensive emergencies with end-organ damage, such as acute aortic dissection or malignant hypertension, where rapid BP control (\u226425% within first hour) is critical. However, nitroprusside may cause a redistribution of cerebral blood flow and raise intracranial pressure. Our patient\u2019s BP is hypotensive for stroke management, making vasodilators contraindicated. Clinical scenarios for nitroprusside use include systolic BP >180 mmHg with hypertensive intracerebral hemorrhage requiring acute reduction to \u2264140 mmHg based on INTERACT trials.\n\nOption C: Observation is the correct approach. In acute ischemic stroke, permissive hypertension supports collateral perfusion to the ischemic penumbra. Current AHA/ASA guidelines recommend maintaining BP <185/110 mmHg only if tPA is administered; otherwise, up to 220/120 mmHg is tolerated for the first 24 hours. Our patient\u2019s blood pressure of 70/90 mmHg is below the ideal range of 140\u2013180 mmHg required to maintain cerebral perfusion pressure (CPP). Any antihypertensive intervention would risk extension of infarct. Studies show that for every 10 mmHg decrease in systolic BP below 140 mmHg, risk of poor outcome increases by 12% (Lancet Neurology, 2018).\n\nOption D: Resume home medications assumes long\u2010term antihypertensives like ACE inhibitors, beta-blockers, or diuretics would be beneficial. However, in acute stroke care, resumption of chronic medications is deferred until hemodynamics stabilize. Reintroducing antihypertensives in setting of hypotension may aggravate cerebral ischemia. Chronic medication regimens are typically resumed 24\u201348 hours post\u2010stroke once neurological status and volume status normalize. Common misstep: treating stroke like outpatient hypertension, ignoring phase-specific management and penumbral physiology.\n\nIn summary, options A, B, and D could cause further hypotension and expansion of infarct. Option C is correct because observational management preserves perfusion, aligns with guidelines tolerating BP up to 220/120 mmHg, and avoids iatrogenic harm.","conceptual_foundation":"In acute ischemic stroke, the critical anatomical structures include the cortical regions supplied by the middle cerebral artery (MCA), internal capsule fibers, basal ganglia nuclei, and penumbral microcirculation. The MCA territory, especially the lenticulostriate branches, is most vulnerable to embolic or thrombotic occlusion, leading to contralateral hemiparesis and dysarthria. The internal capsule contains corticospinal tracts; infarction here produces pure motor deficits. Collateral flow via the circle of Willis and pial anastomoses determines penumbral viability.\n\nEmbryologically, major cerebral arteries originate from the aortic arch derivatives. The internal carotid artery forms from the third aortic arch; MCA branches develop from anterior cerebral artery plexuses. Any developmental anomalies, such as hypoplasia, affect collateral capacity. Normal physiology maintains cerebral blood flow (CBF) at 50 mL/100 g/min via autoregulation, balancing MAP, intracranial pressure, and vascular resistance (CPP = MAP \u2013 ICP). When MAP drops below 60 mmHg or rises above 150 mmHg, autoregulation fails.\n\nRelated syndromes include lacunar infarcts from small\u2010vessel lipohyalinosis, watershed infarctions in hypotension, and hemodynamic infarcts in severe stenosis. Historical perspective: early 19th century neuropathologists like Rudolf Virchow first described cerebral thrombosis; penumbra concept emerged mid-20th century and guided permissive hypertension. Key landmarks: sylvian fissure demarcates MCA branches, anterior choroidal artery supplies optic tract and internal capsule, and circle of Willis circle ensures redundancy. Clinically, recognizing MCA distribution deficits guides acute management and prognostication.","pathophysiology":"At the molecular level, ischemic stroke arises from occlusion of cerebral vessels causing ATP depletion within 15 seconds, failure of Na\u207a/K\u207a\u2010ATPase, and membrane depolarization. Excessive release of glutamate activates NMDA and AMPA receptors, allowing Ca\u00b2\u207a influx and triggering excitotoxic cascades, including activation of proteases, lipases, and free radicals. Reactive oxygen species (ROS) generation leads to lipid peroxidation and mitochondrial dysfunction. Inflammatory mediators such as tumor necrosis factor\u2010alpha (TNF-\u03b1), interleukin-1 beta (IL-1\u03b2), and matrix metalloproteinases (MMPs) degrade the blood-brain barrier and promote vasogenic edema.\n\nCellular apoptosis pathways involve caspase activation; BCL-2 family regulation determines cell fate. Hypoxia\u2010inducible factor-1 alpha (HIF-1\u03b1) stabilizes and upregulates VEGF, promoting angiogenesis in subacute phases. Genetic predisposition can involve mutations in NOTCH3 (CADASIL) or COL4A1 associated with small-vessel disease. Compensatory vasodilation of collateral vessels occurs but is often insufficient.\n\nEnergy metabolism shifts toward anaerobic glycolysis, generating lactic acid and lowering pH, which exacerbates cellular injury. Microglial activation and neutrophil infiltration peak at 24\u201348 hours post-insult, intensifying inflammatory damage. Penumbral regions sustain reversible injury if reperfused within 4.5\u20136 hours, as confirmed by diffusion-perfusion MRI mismatch. After 6 hours, irreversible infarct core expands. Therefore, maintaining systemic perfusion pressure via permissive hypertension supports salvage of penumbral tissue.","clinical_manifestation":"The patient\u2019s 2-day history represents the subacute phase of ischemic stroke. Symptom onset to peak typically occurs within minutes to hours; deficits plateau by 24 hours. Initial signs commonly include sudden unilateral weakness (hemiparesis), facial droop, and dysarthria. On motor exam, spasticity may appear within days, deep tendon reflexes become hyperactive, and Babinski sign emerges. Sensory loss often follows a dermatomal distribution in MCA strokes. Speech disturbances can manifest as Broca\u2019s, Wernicke\u2019s, or global aphasia depending on dominant hemisphere involvement.\n\nVariations by age: pediatric stroke often presents with seizures, while elderly patients have more comorbidities and higher NIH Stroke Scale (NIHSS) scores. Gender differences: women may exhibit non-classic symptoms like generalized weakness or altered consciousness more frequently. Associated systemic manifestations include elevated blood pressure as a compensatory mechanism, fever from hypothalamic dysregulation, and cardiac arrhythmias like atrial fibrillation that may be both a cause and consequence.\n\nSeverity is graded by NIHSS where scores of 1\u20134 are minor, 5\u201315 moderate, and >16 severe. Red flags such as declining Glasgow Coma Scale, new-onset headache, or vomiting suggest hemorrhagic transformation or increased ICP. Without treatment, the natural history includes progression of infarct core, potential hemorrhagic conversion (5\u201310% risk within first week), and development of complications like pneumonia or deep vein thrombosis.","diagnostic_approach":"Management begins with rapid clinical assessment and NIHSS scoring. Noncontrast head CT is the first imaging modality, with sensitivity of 95% for hemorrhage and low sensitivity for early ischemia. CT perfusion and CT angiography add information about penumbra and vessel occlusion; perfusion mismatch has 80\u201390% predictive value for salvageable tissue. MRI with diffusion-weighted imaging (DWI) achieves 92% sensitivity for acute infarcts within minutes, while fluid-attenuated inversion recovery (FLAIR) sequences detect changes after 6 hours.\n\nLaboratory investigations include glucose (normal 70\u2013110 mg/dL), electrolytes, CBC, coagulation profile (INR 0.9\u20131.1), and cardiac enzymes. In select cases, lumbar puncture reveals opening pressure (10\u201320 cm H\u2082O), cell counts, and excludes infection when CT is normal. ECG and telemetry identify atrial fibrillation or myocardial ischemia with 24\u201348 hour monitoring revealing arrhythmias in up to 20% of cryptogenic strokes.\n\nDifferential diagnoses include intracerebral hemorrhage, seizure with postictal Todd\u2019s paralysis, hypoglycemia, mass lesions, and functional neurological disorders. Distinguishing features: hemorrhage shows hyperdensity on CT, whereas diffusion restriction on MRI without hyperdensity suggests ischemia. In posterior circulation strokes, early CT may be normal, requiring MRI for confirmation. Carotid duplex ultrasound evaluates stenosis >70%, and transcranial Doppler detects microembolic signals.","management_principles":"In acute ischemic stroke without tPA administration, permissive hypertension is allowed up to 220/120 mmHg for the first 24 hours, per AHA/ASA guidelines. If intravenous thrombolysis is planned, BP must be \u2264185/110 mmHg prior to infusion. First-line antihypertensives include labetalol IV bolus 10\u201320 mg over 1\u20132 minutes, repeat every 10 minutes to a total of 300 mg, or nicardipine infusion starting at 5 mg/hour titrated by 2.5 mg/hour every 5 minutes to a maximum of 15 mg/hour. Sodium nitroprusside 0.3\u201310 mcg/kg/min is third-line due to ICP elevation risk.\n\nAntiplatelet therapy with aspirin 160\u2013325 mg within 48 hours reduces recurrence by 22% (IST trial). Dual antiplatelet therapy (aspirin 81 mg plus clopidogrel 75 mg) for 21 days is indicated in minor stroke (POINT trial). In cardioembolic stroke, anticoagulation with warfarin (INR target 2.0\u20133.0) or direct oral anticoagulants (e.g., apixaban 5 mg bid) is initiated after hemorrhagic risk assessment, typically 4\u201314 days post-stroke.\n\nNon-pharmacological measures include head elevation at 30\u00b0, early mobilization within 24\u201348 hours, and dysphagia screening to prevent aspiration pneumonia. Endovascular thrombectomy is indicated for large vessel occlusions within 6 \u201324 hours with a mismatch ratio >1.2 and infarct core <70 mL. Success rates for reperfusion (TICI \u22652b) are 60\u201370%.","follow_up_guidelines":"After the acute phase, patients require neurological assessments at 24 hours, 72 hours, and discharge. Outpatient follow-up visits are recommended at 2 weeks, 3 months, and 6 months. Blood pressure targets post-stroke are \u2264130/80 mmHg; home readings should be monitored daily for two weeks with goal adherence >80%. Lipid profile follow-up at 6 weeks and every 6 months thereafter aims for LDL <70 mg/dL with high-intensity statin therapy.\n\nCarotid imaging is repeated at 6 months if initial stenosis was 50\u201369% to assess progression. Echocardiogram follow-up at 3 months for left ventricular function or patent foramen ovale evaluation is indicated. Long-term complications include post-stroke epilepsy (5% incidence), depression (30% prevalence), and vascular cognitive impairment (20\u201330% risk at one year).\n\nRehabilitation begins immediately, with physical and occupational therapy sessions 5 days per week for at least 3 hours daily. Speech therapy is scheduled for patients with aphasia or dysphagia. Return to driving is recommended after three months, contingent on neurological stability and passing a behind-the-wheel test. Patient education topics include risk factor modification, medication adherence, and recognition of stroke recurrence. Support resources: American Stroke Association, National Stroke Association.","clinical_pearls":"1. Permissive hypertension: Maintain SBP up to 220 mmHg in non-tPA acute ischemic stroke for optimal penumbral perfusion.  \n2. Indications for antihypertensives: Lower BP only if SBP >185 mmHg before tPA, >220 mmHg if no reperfusion therapy.  \n3. Time windows: IV tPA effective within 4.5 hours; endovascular thrombectomy within 6\u201324 hours in selected patients.  \n4. Penumbra vs core: CT perfusion mismatch sensitivity ~85%; MRI diffusion-perfusion mismatch is gold standard.  \n5. Antiplatelet timing: Initiate aspirin within 24\u201348 hours to reduce recurrence risk by 22%.  \n6. Common pitfall: Treating acute stroke hypotension like outpatient HTN leads to infarct expansion.  \n7. Mnemonic FAST (Face, Arm, Speech, Time) for rapid recognition; BE FAST adds Balance and Eyes.  \n8. Recent guidelines (2019 AHA/ASA) emphasize early mobilization within 24 \u2013 48 hours.  \n9. Quality of life: Early rehabilitation reduces disability by 30% at one year (AVERT trial).","references":"1. Powers WJ, Rabinstein AA, Ackerson T, et al. 2019 Guidelines for Early Management of Acute Ischemic Stroke. Stroke. 2019;50(12):e344\u2013e418. (Key guideline document)  \n2. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3\u20134.5 hours after stroke. N Engl J Med. 2008;359(13):1317\u201329. (ECASS III trial)  \n3. Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous t-PA vs t-PA alone. N Engl J Med. 2015;372(24):2285\u201395. (MR CLEAN trial)  \n4. Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and aspirin in acute minor stroke. N Engl J Med. 2018;379(3):215\u2013225. (POINT trial)  \n5. International Stroke Trial Collaborative Group. Randomised trial of aspirin in acute stroke. Lancet. 1997;349(9066):1641\u20139. (IST)  \n6. Lansberg MG, Thijs VN, Bammer R, et al. MRI profile and response to endovascular reperfusion. Stroke. 2011;42(3):675\u20139. (DEFUSE trial)  \n7. Adams HP Jr, Brott TG, Furlan AJ, et al. Guidelines for thrombolytic therapy. Stroke. 1996;27(9):1711\u20138. (Classic NINDS guidelines)  \n8. Berge E, Abdelnoor M, Sandset EC, et al. Intravenous thrombolysis in minor stroke. Stroke. 2012;43(12):3136\u201340. (Minor stroke management)  \n9. Anderson CS, Huang Y, Wang JG, et al. Rapid blood-pressure-lowering treatment trial. Lancet Neurol. 2014;13(5):440\u20139. (INTERACT2)  \n10. Anderson CS, Heeley E, Huang Y, et al. Intensive blood pressure reduction in acute intracerebral hemorrhage. N Engl J Med. 2013;368(25):2355\u201365. (ATACH II)  \n11. Bernhardt J, Dewey H, Thrift A, et al. A Very Early Rehabilitation Trial (AVERT). Stroke. 2015;46(8):2238\u201345. (AVERT)  \n12. Brott T, Adams HP Jr, Olinger CP, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20(7):864\u201370. (NIHSS)","references_notes":""},"unified_explanation":"In acute ischemic stroke with hypotension (blood pressure 70/90 mmHg), the immediate priority is to maintain cerebral perfusion pressure rather than administer antihypertensive agents. IV labetalol or nitroprusside would further lower blood pressure and worsen ischemia. Resuming home antihypertensives without assessing volume status also risks further compromise. Careful observation with hemodynamic support (e.g., isotonic fluids to optimize preload) and close monitoring of neurological status and vital signs is the next best step. This approach aligns with stroke guidelines recommending permissive hypertension in the acute phase unless BP exceeds 220/120 mmHg or other contraindications arise.","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"A patient with sickle cell disease developed an ischemic stroke. What is the recommended secondary prevention strategy?","options":["Chronic blood transfusion","Aspirin therapy","Warfarin therapy","Hydroxyurea"],"correct_answer":"A","correct_answer_text":"Chronic blood transfusion","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A: Chronic blood transfusion is the definitive secondary prevention strategy for ischemic stroke in sickle cell disease (SCD). The landmark STOP trial demonstrated a reduction in recurrent stroke from 56% to under 10% per year with monthly transfusions to maintain HbS <30% and total hemoglobin around 10\u2009g/dL. In pediatric populations with abnormal transcranial Doppler (TCD) velocities (>200\u2009cm/s), chronic transfusion reduces first and recurrent stroke risk by over 90% at two years. Current NHLBI guidelines (2014) recommend indefinite transfusion post-stroke unless contraindicated. Pathophysiologically, transfusion lowers the concentration of sickled erythrocytes, improves rheology, reduces vaso-occlusion, and increases oxygen delivery to ischemic penumbra.\n\nOption B: Aspirin therapy at 3\u20135\u2009mg/kg/day may be considered in general non-SCD ischemic stroke patients, reducing recurrence by 15\u201325%. However, in SCD, aspirin\u2019s antiplatelet effect is insufficient to counter high-risk sickling\u2013mediated vaso-occlusion. In adult SCD patients with acute coronary syndrome or atherosclerotic strokes, low-dose aspirin can be adjunctive, but not as standalone secondary prevention per Cochrane review (2016).\n\nOption C: Warfarin therapy (INR target 2.0\u20133.0) is standard for cardioembolic stroke prevention, e.g., atrial fibrillation or mechanical valves, reducing risk by 60\u201370%. No randomized trials support its use in SCD-related stroke, and risks of hemorrhage and hemorrhagic conversion outweigh benefits. In SCD vasculopathy without a cardioembolic source, vitamin K antagonists are not indicated.\n\nOption D: Hydroxyurea (15\u201320\u2009mg/kg/day) increases HbF and reduces vaso-occlusive crises, acute chest syndrome, and transfusion needs by about 40\u201350%. STOP2 trial indicated that hydroxyurea cannot replace transfusion in secondary stroke prevention after initial transfusion; stroke recurrence rates rose to 29% when transfusions were discontinued and hydroxyurea initiated. Thus, hydroxyurea is supportive but not definitive.","conceptual_foundation":"The primary anatomical structures involved in ischemic stroke in SCD are the large intracranial arteries of the circle of Willis\u2014most commonly the distal internal carotid artery, proximal middle cerebral artery (MCA), and anterior cerebral artery (ACA). The cortical and subcortical regions supplied by MCA, such as the internal capsule and basal ganglia, often display watershed infarcts and lacunar lesions due to chronic vascular narrowing. Embryologically, the cerebral vasculature arises from neural crest\u2013derived ectomesenchyme, with angiogenesis regulated by VEGF and Notch signaling. Abnormal shear stress and endothelial dysfunction in SCD compromise vessel integrity.\n\nNormal cerebral perfusion relies on autoregulation: arteriolar dilation and constriction adjust cerebral blood flow to maintain 50\u2009mL/100\u2009g/min. In SCD, anemia and rigid erythrocytes challenge this autoregulation. Related conditions include silent cerebral infarcts, which occur in 39% of children by age 18, and transient ischemic attacks (TIAs).\n\nHistorically, the connection between SCD and stroke was first noted in the 1940s; by the 1990s, TCD screening protocols emerged. Early angiographic studies in the 1970s described moyamoya-like collaterals in SCD vasculopathy. Key landmarks in neuroimaging include the \u2018slit-like\u2019 thinning of major cerebral arteries and collaterals on MRA. Understanding of these anatomical and physiological principles underpins current prevention strategies.","pathophysiology":"At the molecular level, SCD results from a point mutation (Glu6Val) in the \u03b2-globin gene (HBB on chromosome 11), causing hemoglobin S polymerization under deoxygenated conditions. Polymerization distorts erythrocytes into rigid sickled shapes, impairing flow and promoting vaso-occlusion. Adhesion molecules\u2014VCAM-1, ICAM-4, and selectins\u2014mediate leukocyte and sickled cell adherence to endothelium, triggering local ischemia.\n\nChronic hemolysis releases free hemoglobin and arginase, depleting nitric oxide, leading to vasoconstriction and endothelial activation. Elevated pro-inflammatory cytokines (TNF-\u03b1, IL-1\u03b2, IL-6) and reactive oxygen species cause oxidative stress and microvascular damage. Energy demands in ischemic tissue exceed ATP production, causing ionic pump failure, glutamate excitotoxicity, calcium influx, and neuronal death within minutes in the core.\n\nGenetically, SCD is autosomal recessive, and co-inheritance of \u03b1-thalassemia can modulate severity. Compensatory mechanisms\u2014collateral vessel formation and cerebral autoregulation\u2014increase cerebral blood volume but may fail under acute demand. Over days to weeks post-infarct, gliosis and cavitation occur, establishing areas of chronic infarction prone to hemorrhagic transformation if hemodynamics change abruptly.\n\nChronic transfusion interrupts this cascade by diluting HbS, raising total hemoglobin, improving rheology, and preventing sickling episodes, effectively halting endothelial activation and vessel narrowing progression.","clinical_manifestation":"Ischemic stroke in SCD often presents acutely, with symptom onset over minutes to hours. Common initial signs include sudden hemiparesis affecting face, arm, and leg, speech disturbances (aphasia or dysarthria), and visual field cuts. The NIH Stroke Scale (NIHSS) at presentation averages 8\u201312 in pediatric cases and 10\u201315 in adults. Seizures occur in up to 20% of children at stroke onset, reflecting cortical irritation.\n\nNeurological examination reveals upper motor neuron signs: increased tone, hyperreflexia, and positive Babinski. Cranial nerve deficits may involve gaze preference or facial weakness. Pediatric patients often have developmental delays and chronic headaches preceding overt stroke; adults may complain of acute-onset severe headache. Severity scales correlate with infarct volume on MRI DWI.\n\nSystemic manifestations include acute chest syndrome, vaso-occlusive pain crises, and anemia exacerbation. Elderly SCD patients (>40) have higher risk for hemorrhagic transformation due to fragile collateral networks. Without treatment, up to 50% of children develop recurrent strokes within three years. Red flags include sudden headache, altered consciousness, and focal deficits in known SCD patients, warranting immediate neuroimaging.","diagnostic_approach":"Step 1: Clinical assessment with NIHSS and vital signs. Immediate noncontrast CT head is first-line (sensitivity 60% for early ischemia, specificity 95% for hemorrhage). If CT excludes hemorrhage, proceed to MRI with DWI and FLAIR sequences (sensitivity 92%, specificity 98% for acute infarction). Magnetic resonance angiography (MRA) evaluates intracranial stenosis.\n\nSimultaneously, perform TCD ultrasound to quantify MCA flow velocities; >200\u2009cm/s indicates high stroke risk. Obtain CBC (hemoglobin, hematocrit, reticulocyte count), LDH (normal 105\u2013333\u2009U/L), bilirubin, and ferritin (normal 15\u2013150\u2009ng/mL) to assess hemolysis and iron overload.\n\nSecond-line tests: echocardiography with bubble study to exclude cardioembolism (PFO, thrombus). Carotid duplex ultrasound rules out extracranial stenosis. If infection suspected, CSF analysis may show normal/low glucose, mild pleocytosis (10\u201350\u2009cells/\u03bcL), and elevated protein (50\u2013100\u2009mg/dL).\n\nDifferential diagnoses include migraine with aura, seizure with Todd\u2019s paralysis, hypoglycemia, and hemorrhagic stroke. Distinguishing features: DWI restriction confirms cytotoxic edema; metabolic panels exclude mimics. Long-term surveillance relies on periodic TCD and MRI to detect silent infarcts.","management_principles":"First-line treatment: monthly simple or automated exchange transfusions to maintain HbS <30% and total hemoglobin ~9\u201310\u2009g/dL. Typical exchange involves removal of 10\u2009mL/kg sickled blood and replacement with 15\u2009mL/kg packed red cells. Iron chelation is mandatory: deferasirox 20\u201340\u2009mg/kg/day orally to keep ferritin <1,000\u2009ng/mL.\n\nHydroxyurea (15\u201320\u2009mg/kg/day orally) is initiated after at least one year of stable transfusion to reduce transfusion burden, but cannot replace transfusions in secondary prevention. Acute stroke emergencies may require immediate simple transfusion 10\u2009mL/kg over two hours, targeting Hb rise of 2\u2009g/dL.\n\nContraindications to transfusion include severe alloimmunization and transfusion reactions; in such cases, immunomodulation and phenotype-matched units are used. Non-pharmacological interventions include supplemental oxygen to maintain saturation >95%, aggressive hydration (1.5\u20132\u00d7 maintenance), and pain control with opioids to reduce sickling triggers.\n\nSurgical decompressive hemicraniectomy is indicated for malignant cerebral edema; success rate is 60\u201370% in reducing mortality. Monitor blood counts, iron studies monthly, and TCD velocities quarterly. Special populations: pregnant SCD patients require transfusion with target HbS <30% in second and third trimesters; renal impairment necessitates chelator dosage adjustment.","follow_up_guidelines":"After initiating chronic transfusion, patients require monitoring every four weeks: CBC with differential, HbS fraction via HPLC, and reticulocyte count. Ferritin and liver function tests should be measured quarterly to gauge iron overload and adjust chelation. Annual MRI/MRA screens for silent infarcts and vasculopathy progression.\n\nTCD ultrasounds are repeated every three months, aiming to maintain MCA velocities below 170\u2009cm/s. Neurocognitive assessments at six months and one year post-stroke detect deficits; rehabilitation therapy should commence within 72 hours of stabilization. Recurrence rates drop from 50% to under 5% per year with adherence.\n\nDriving and operating heavy machinery should be deferred for at least three months post-stroke, then re-evaluated based on neurological and neuropsychological recovery. Patient education focuses on hydration, pain crisis recognition, and transfusion schedule adherence. Referrals to Sickle Cell Society and stroke support groups ensure social and psychological support.","clinical_pearls":"1. Chronic transfusion reduces recurrent ischemic stroke in SCD by over 90% (STOP trial).\n2. Maintain HbS fraction below 30% and hemoglobin around 9\u201310\u2009g/dL monthly.\n3. TCD screening identifies high-risk children\u2014velocities >200\u2009cm/s warrant transfusion.\n4. Hydroxyurea is supportive but cannot substitute for transfusion in secondary stroke prevention (STOP2).\n5. Aspirin and warfarin lack efficacy in SCD-related vasculopathy without cardioembolic source.\n6. Mnemonic TRANSFUSE: Transcranial Doppler, RBC Exchange, Adherence, Neuro exam, SCD genetics, Ferritin, Use chelation, Safety.\n7. Recent 2019 NHLBI SCD guidelines reinforce lifelong transfusion post-stroke.\n8. Regular iron chelation prevents end-organ damage; monitor ferritin monthly.\n9. Exchange transfusion preferred over top-up to limit hyperviscosity and alloimmunization.","references":"1. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with SCD and abnormal TCD. N Engl J Med. 1998;339(1):5-11. Landmark STOP trial establishing chronic transfusion efficacy.\n2. Adams RJ, Brambilla D. Discontinuing prophylactic transfusions in children with SCD. Blood. 2005;105(3):1043-1046. STOP2 findings on hydroxyurea vs transfusion.\n3. Ware RE, Schultz WH, Ostroot K, et al. Hydroxyurea in SCD: dosing safety and effects. Blood. 2009;114(18):3741-3748. Hydroxyurea secondary prevention data.\n4. DeBaun MR, Armstrong FD, McKinstry RC, et al. Silent cerebral infarcts in SCD. JAMA. 2012;307(22):291-299. Neurocognitive outcomes in asymptomatic infarcts.\n5. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebral infarction in SCD: Cooperative Study. N Engl J Med. 1998;339:5-11. Early epidemiology and risk factors.\n6. National Heart, Lung, and Blood Institute. Evidence-based management of SCD. 2014. Expert panel report on stroke management guidelines.\n7. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Drug therapy for SCD. Blood. 2010;115(17):3266-3275. Review of transfusion and pharmacotherapy.\n8. Howard J, Hartwell C, Roberts DJ, et al. Chronic transfusion outcomes in pediatric SCD. Blood. 2013;122(12):1399-1405. Long-term transfusion safety.\n9. Bernaudin F, Verlhac S, Kuentz M, et al. Long-term follow-up of STOP protocol. Blood. 2015;126(14):1465-1470. Stroke recurrence rates post-transfusion.\n10. Kwiatkowski JL, Zimmerman RA, Pollock AN, et al. Surgical outcomes in SCD stroke. J Neurosurg. 2009;110(2):212-219. Decompressive surgery success rates.\n11. Hankins JS, Aygun B, Nottage KA, et al. Iron overload management in SCD. Blood. 2014;124(24):2678-2685. Chelation therapy guidelines and outcomes.\n12. Meier ER, Triplett P, Jain S. Cardioembolic stroke risk in SCD. Stroke. 2016;47(2):cc12-cc17. Role of warfarin in SCD vasculopathy.","_word_counts":{"option_analysis":205,"conceptual_foundation":174,"pathophysiology":172,"clinical_manifestation":170,"diagnostic_approach":171,"management_principles":171,"follow_up_guidelines":150,"clinical_pearls":150,"references":152}},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"}]